It’s been 10 years since Jenny and Karl Herz started in business. Over the past 10 years they’ve launched Biointelect and Biocelect businesses to help secure approval and distribution for new medicines into Australia.
Biointelect is a strategic planning and commercialisation firm for the biopharmaceutical and medical device sector including commercial, government and not-for-profit organisations.
Biointelect helps its clients develop and drive strategy, identify and evaluate new business opportunities and engage the right partners. The strategy consulting involves therapeutic development from start up through to post launch, with an Australian and a Global perspective.
Biointelect’s mission is to bring science to market.
Biocelect works with local and overseas partners to bring critical pharmaceutical products and medical technology solutions to the Australian market.
In addition to our travel range, infectious disease portfolio and novel medical diagnostics, Biocelect is the sponsor of the Novavax COVID-19 Vaccine, NVX-CoV2373 for Australia and New Zealand.
Biocelect’s mission is to build pathways to patients.
In this Australian Health Journal interview, Jenny and Karl talk about the journey the husband and wife team took to get the Novavax COVID-19 vaccine (Nuvaxovid) approved and distributed in Australia. The journey didn’t just include talented and diverse skilled staff but also their children working in both organisations.
-
Circular use of medical device technology and evolving policy and regulatory frameworks
Healthcare sustainability is increasingly becoming a strategic priority, extending beyond environmental goals to influence procurement, regulation, costs and supply-chain resilience. Against this backdrop, medical device reprocessing is emerging as a potential pathway towards a more circular healthcare system.
-
Misinformation impacts routine vaccines
More significant changes in recent years have been health-related misinformation eroding trust in healthcare professionals, leading to people seeking alternative treatments or avoiding medical advice altogether. This can make it more difficult for healthcare professionals to provide effective treatment and care.
Recent vaccines delivered as part of the COVID-19 response, are having a consequential impact on the uptake of routine vaccines.
Australian Health Journal spoke with Dr Paul Griffin, an Infectious Diseases Physician and Microbiologist at Mater Health, and who has been involved in over 150 clinical trials in the field of infectious disease.
Paul talks about the importance of having reputable sources of information that can used to encourage people to understand what is involved in clinical trials and the roles of vaccines.
-
Lived experience & human-centred design in healthcare
Recognised as one of the Top 100 Women of Influence by The Australian Financial Review, Melanie Tran is a visionary leader whose work lies at the intersection of design, technology, health, disability, and education. With a focus on human-centred design, digital strategy, and service design, she leads transformative initiatives as a Manager in Design, Digital and Data at Nous Group, a global consulting firm. Her work is driven by a deep passion for using creativity and technology to solve complex social challenges.
